AstraZeneca speeds China R&D timetable with WuXi pact; Roche narrows list of possible U.S. research sites; Merck touts sleep drug data;

Conversations on Twitter :

 @FierceBiotech: What's killing biopharma's R&D success rate? Story | Follow @FierceBiotech

 @JohnCFierce: AZ does a China development deal on RA drug with WuXi AppTech. Kinda similar to SFJ pacts. Look for more of these. Report | Follow @JohnCFierce

> AstraZeneca ($AZN) has struck a deal with WuXi AppTec to develop an experimental anti-inflammatory drug in China. WuXi will now take the lead on clinical development in China on MEDI-5117 as AstraZeneca retains control in Europe and the U.S. AstraZeneca's Bahija Jallal tells Reuters that the deal could cut years out of the amount of time it would normally take to get the drug to an approval in China. And the research pact could be a model for others as well. Report

> Roche ($RHHBY) has narrowed a list of potential sites for a new clinical research center to a shortlist of four: two locations in New Jersey and two others in New York. Roche is planning to retain 240 researchers in the area after it closes its sprawling hub in Nutley, NJ. Story

> Merck ($MRK) is touting new late-stage data for its sleep drug Suvorexant. The drug blocks orexins, which promote wakefulness. Release

> Shares of Silence Therapeutics jumped on the news that "pre-clinical models demonstrated the efficacy of Atu111 in acute lung injury." Release

> Cambridge, MA-based DART Therapeutics named co-founder and executive chairman Eugene W. Williams to a full-time role as CEO while Ernest D. Bush Ph.D. joins as chief scientific officer. Release

Pharma News

 @FiercePharma: Truvada use expected to be limited in U.S. Story | Follow @FiercePharma

> FDA gives generic drugs 'super' status. Report

> Biogen Idec cashes out royalties on Benlysta. Article

> Budget impasse imperils FDA user fees programs. More

Medical Device News

 @FierceMedDev: Budget battles could unravel the massive device/drug user fee renewal agreed to earlier this summer. More | Follow @FierceMedDev

 @MarkHFierce: Another day, another 510(k) for an Impella heart pump variation. The company is working hard to broaden its market. Release | Follow @MarkHFierce

 @DamianFierce: San Antonio's BiO2 Medical pulled in $12M to market its venous catheter. News | Follow @DamianFierce

> Cook expands into ENT device arena. More

> Minnesota medtech accelerator debuts, with Medtronic vet at the helm. Item

Biotech IT News

> Pharma flocks to social media analytics. Story

> Pinterest attracts more pharma outfits. Report

> ENCODE generates 15 trillion bytes of data for researchers. Article

> Informatics research may kill old-school databases. More

CRO News

> Top Emerging CRO Markets. Special Report

> Icon teams with Dublin university for drug development. Item

> FDA slaps DPT with warning letter over sterility concerns. Article

> CMO Patheon sells off clinical packaging biz. More

And Finally… In a new study investigators found that stress causes some people to retain as much salt as they would normally get in an order of French fries. Release

 

Suggested Articles

Out of options, Tocagen will become Forte Biosciences’ route to the public markets through an all-stock reverse merger.

Reich co-founded Effector and served as its SVP of research but has moved on to take up the CSO position at Turning Point Therapeutics.

BioMarin’s hemophilia A drug has been set an Aug. 21 PDUFA date as the California biotech looks to gain a speedy approval.